Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: A systematic review and meta-analysis

Addiction

Volumn 110, Issue 1, 2015, Pages 38-48

  Zhou, Xinyu ^a   Qin, Bin ^a   Del Giovane, Cinzia ^b   Pan, Junxi ^a   Gentile, Salvatore ^c   Liu, Yiyun ^a   Lan, Xinghui ^d   Yu, Jia ^a   Xie, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c ASL Salerno   (Italy)

^d CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Adolescents; Antidepressants; Major depressive disorder; Meta analysis; Substance use disorders; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; CHILD; COMPLICATION; DEPRESSIVE DISORDER; FEMALE; HEALTH CARE QUALITY; HUMAN; MALE; META ANALYSIS; PSYCHIATRIC DIAGNOSIS; PUBLISHING; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; SUICIDE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; PUBLICATION BIAS; QUALITY ASSURANCE, HEALTH CARE; SUBSTANCE-RELATED DISORDERS; SUICIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923205377     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12698     Document Type: Review

References (53)

1. Kaminer Y., Connor D. F., Curry J. F. Comorbid adolescent substance use and major depressive disorders: a review. Psychiatry (Edgmont) 2007; 4: 32-43.
2. Andrews G., Wilkinson D. D. Prevention of mental disorders in young people. Med J Aust 2002; 177: S97-100.
3. Sawyer M. G., Arney F. M., Baghurst P. A., Clark J. J., Graetz B. W., Kosky R. J. etal. Mental Health of Young People in Australia: Child and Adolescent Component of the National Survey of Mental Health and Wellbeing. Mental Health and Special Programs Branch, Commonwealth Department of Health and Aged Care. 2000. Available at: http://www.health.gov.au/internet/publications/publishing.nsf/Content/mental-pubs-m-young-toc (accessed 10 September 2013) (Archived at http://www.webcitation.org/6RxUXLkXm on 19 August 2014).
4. Birmaher B., Ryan N. D., Williamson D. E., Brent D. A., Kaufman J., Dahl R. E. etal. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35: 1427-1439.
5. Teesson M., Proudfoot H. Comorbid mental disorders and substance use disorders: epidemiology, prevention and treatment. University of New South Wales, National Drug and Alcohol Research Centre. Canberra: Commonwealth Department of Health and Ageing; 2003.
6. Lewinsohn P. M., Rohde P., Seeley J. R. Psychosocial risk factors for future adolescent suicide attempts. J Consult Clin Psychol 1994; 62: 297-305.
7. King C. A., Naylor M. W., Hill E. M., Shain B. N., Greden J. F. Dysthymia characteristic of heavy alcohol use in depressed adolescents. Biol Psychiatry 1993; 33: 210-212.
8. Grella C. E., Hser Y. I., Joshi V., Rounds-Bryant J. Drug treatment outcomes for adolescents with comorbid mental and substance use disorders. J Nerv Ment Dis 2001; 189: 384-392.
9. Rohde P., Lewinsohn P. M., Seeley J. R. Psychiatric comorbidity with problematic alcohol use in high school students. J Am Acad Child Adolesc Psychiatry 1996; 35: 101-109.
10. Emslie G. J., Heiligenstein J. H., Wagner K. D., Hoog S. L., Ernest D. E., Brown E. etal. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205-1215.
11. March J., Silva S., Petrycki S., Curry J., Wells K., Fairbank J. etal. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004; 292: 807-820.
12. Whitmore E. A., Riggs P. D. Developmentally informed diagnostic and treatment considerations in comorbid conditions. In: Liddle H. A., Rowe C. L., editors. Adolescent Substance Abuse: Research and Clinical Advances. New York, NY: Cambridge University Press; 2006, pp. 264-283.
13. Tripp J. C., Skidmore J. R., Cui R., Tate S. R. Impact of physical health on treatment for co-occurring depression and substance dependence. J Dual Diagn 2013; 9: 239-248.
14. Perron B. E., Bunger A., Bender K., Vaughn M. G., Howard M. O. Treatment guidelines for substance use disorders and serious mental illnesses: do they address co-occurring disorders? Subst Use Misuse 2010; 45: 1262-1278.
15. Nunes E. V., Levin F. R. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291: 1887-1896.
16. Torrens M., Fonseca F., Mateu G., Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend 2005; 78: 1-22.
17. Birmaher B., Brent D., AACAP Work Group on Quality Issues, Bernet W., Bukstein O., Walter H. etal. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46: 1503-1526.
18. National Health and Medical Research Council (NHMRC). Clinical Practice Guidelines: Depression in Adolescents and Young Adults. 2011. Available at: http://www.beyondblue.org.au/resources/health-professionals/clinical-practice-guidelines/adolescents-and-young-adults-guidelines (accessed 28 September 2013) (Archived at http://www.webcitation.org/6RxUyF3KV on 19 August 2014).
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association; 1980.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, revised 3rd edn. Washington, DC: American Psychiatric Association; 1987.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association; 1994.
22. Bauer M., Whybrow P. C., Angst J., Versiani M., Moller H. J., World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43.
23. Poznanski E. O., Mokros H. B. Children's Depression Rating Scale Revised. Los Angeles, CA: WPS; 1996.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
25. Riedel M., Möller H. J., Obermeier M., Schennach-Wolff R., Bauer M., Adli M. etal. Response and remission criteria in major depression-a validation of current practice. J Psychiatr Res 2010; 4: 1063-1068.
26. Sobell L. C., Sobell M. B., Leo G. I., Cancilla A. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 1988; 83: 393-402.
27. Hammad T. A. Review and Evaluation of Clinical Data. 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-tab08-hammads-review.pdf (accessed 6 October 2013) (Archived at http://www.webcitation.org/6RxVAlVaw on 19 August 2014).
28. Furukawa T. A., Cipriani A., Barbui C., Brambilla P., Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. Int Clin Psychopharmacol 2005; 20: 49-52.
29. Higgins J. P. T., Green S. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. Chichester, UK: John Wiley & Sons; 2011.
30. Higgins J. P., Thompson S. G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
31. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
32. Hirschtritt M. E., Pagano M. E., Christian K. M., McNamara N. K., Stansbrey R. J., Lingler J. etal. Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders. J Subst Abuse Treat 2012; 42: 366-372.
33. Cornelius J. R., Douaihy A., Bukstein O. G., Daley D. C., Wood S. D., Kelly T. M. etal. Evaluation of cognitive behavioral therapy/ motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addict Behav 2011; 36: 843-848.
34. Geller B., Cooper T. B., Sun K., Zimerman B., Frazier J., Williams M. etal. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37: 171-178.
35. Geller B., Cooper T. B., Watts H. E., Cosby C. M., Fox L. W. Early findings from a pharmacokinetically designed double-blind and placebo-controlled study of lithium for adolescents comorbid with biporal and substance dependency disorders. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 281-299.
36. Brady K. T., Sonne S. C., Malcolm R. J., Randall C. L., Dansky B. S., Simpson K. etal. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol 2002; 10: 276-285.
37. Rohde P. D. Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD. 2008. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00680966 (accessed 6 October 2013) (Archived at http://www.webcitation.org/6RxVI24lj on 19 August 2014).
38. Cornelius J. R., Bukstein O. G., Wood D. S., Kirisci L., Douaihy A., Clark D. B. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav 2009; 34: 905-909.
39. Cornelius J. R., Bukstein O. G., Douaihy A. B., Clark D. B., Chung T. A., Daley D. C. etal. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend 2010; 112: 39-45.
40. Deas D., Randall C. L., Roberts J. S., Anton R. F. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: a pilot study. Hum Psychopharmacol 2000; 15: 461-469.
41. Findling R. L., Pagano M. E., McNamara N. K., Stansbrey R. J., Faber J. E., Lingler J. etal. The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial. Child Adolesc Psychiatry Ment Health 2009; 3: 1-13.
42. Riggs P. D., Mikulich-Gilbertson S. K., Davies R. D., Lohman M., Klein C., Stover S. K. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med 2007; 161: 1026-1034.
43. Hetrick S. E., McKenzie J. E., Cox G. R., Simmons M. B., Merry S. N. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; (11): CD004851.
44. Kranzler H. R., Burleson J. A., Brown J., Babor T. F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20: 1534-1541.
45. Pettinati H. M., Volpicelli J. R., Kranzler H. R., Luck G., Rukstalis M. R., Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000; 24: 1041-1049.
46. US Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. 2004. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm161679.htm (accessed 20 October 2013) (Archived at http://www.webcitation.org/6RxVYcCL3 on 19 August 2014).
47. McCain J. A. Antidepressants and suicide in adolescents and adults: a public health experiment with unintended consequences? PT 2009; 34: 355-378.
48. Dolle K., Schulte-Körne G. The treatment of depressive disorders in children and adolescents. Dtsch Arztebl Int 2013; 110: 854-860.
49. Baer L., Ahern D. K. Statistical problems with small sample size. Am J Psychiatry 1993; 150: 356-357.
50. Wickenberg-Bolin U., Göransson H., Fryknäs M., Gustafsson M. G., Isaksson A. Improved variance estimation of classification performance via reduction of bias caused by small sample size. BMC Bioinformatics 2006; 7: 127.
51. Button K. S., Ioannidis J. P., Mokrysz C., Nosek B. A., Flint J., Robinson E. S. etal. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013; 14: 365-376.
52. Dore G., Mills K., Murray R., Teesson M., Farrugia P. Post-traumatic stress disorder, depression and suicidality in inpatients with substance use disorders. Drug Alcohol Rev 2012; 31: 294-302.
53. Staiger P. K., Thomas A. C., Ricciardelli L. A., McCabe M. P. Identifying depression and anxiety disorders in people presenting for substance use treatment. Med J Aust 2011; 195: S60-63.